Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 25 Pancreatic Neoplasms 19 Neoplasm Metastasis 17 Neuroblastoma 8 Lung Neoplasms 6 Rhabdomyosarcoma 5 Rectal Neoplasms 5 Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Colonic Neoplasms 5 Stomach Neoplasms 4 Small Cell Lung Carcinoma 4 Sarcoma, Ewing 4 Sarcoma 4 Esophageal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Non-Small-Cell Lung 3 Biliary Tract Neoplasms 3 Wilms Tumor 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Kidney Neoplasms 2 Hereditary Sensory and Autonomic Neuropathies 2 Glioma 2 Carcinoma, Neuroendocrine 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2

Interventions

pembrolizumab 12 Cisplatin 11 Specimen Handling 9 Bevacizumab 7 Brachytherapy 6 Platinum 5 Paclitaxel 5 Nivolumab 5 Magnetic Resonance Spectroscopy 5 Human Papillomavirus DNA Tests 5 Colposcopy 5 Carboplatin 5 atezolizumab 4 Gemcitabine 4 Fulvestrant 4 Surveys and Questionnaires 3 Radiotherapy 3 Radiation Dose Hypofractionation 3 Radiation 3 Drug Therapy 3 Blood Specimen Collection 3 1,2-diaminocyclohexaneplatinum II citrate 3 tisotumab vedotin 2 palbociclib 2 lenvatinib 2 Topotecan 2 Restraint, Physical 2 Radiotherapy, Intensity-Modulated 2 Pemetrexed 2 Magnetic Resonance Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Cervical Neoplasms × Irinotecan × 90 days × Clear all

NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡